Review



cdk7 (mo1) mouse mab antibody  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc cdk7 (mo1) mouse mab antibody
    Expression patterns for ( A ) CDK7 and ( B ) <t>pMED1</t> in our HNSCC cohort (magnification 20×, insert 30×). TMAs were immunohistochemically stained for CDK7 and pMED1. The cancer specimen showed a variation in protein expression. The expression of the proteins was homogenous within the patients’ samples, meaning there was little disparity within the staining of cells in a single core. In some HNSCCs the cancer cells showed no staining and accordingly protein expression was considered negative. Throughout the cohort a range of staining intensities was obtained, ( A , B ) illustrate samples of a negative, low, medium, and high protein-expressing tumor specimens.
    Cdk7 (Mo1) Mouse Mab Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk7+(mo1)+mouse+mab+antibody/anti+cdk7/pmc08833595-164-6-33
    Average 90 stars, based on 1 article reviews
    cdk7 (mo1) mouse mab antibody - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "CDK7 Predicts Worse Outcome in Head and Neck Squamous-Cell Cancer"

    Article Title: CDK7 Predicts Worse Outcome in Head and Neck Squamous-Cell Cancer

    Journal: Cancers

    doi: 10.3390/cancers14030492

    Expression patterns for ( A ) CDK7 and ( B ) pMED1 in our HNSCC cohort (magnification 20×, insert 30×). TMAs were immunohistochemically stained for CDK7 and pMED1. The cancer specimen showed a variation in protein expression. The expression of the proteins was homogenous within the patients’ samples, meaning there was little disparity within the staining of cells in a single core. In some HNSCCs the cancer cells showed no staining and accordingly protein expression was considered negative. Throughout the cohort a range of staining intensities was obtained, ( A , B ) illustrate samples of a negative, low, medium, and high protein-expressing tumor specimens.
    Figure Legend Snippet: Expression patterns for ( A ) CDK7 and ( B ) pMED1 in our HNSCC cohort (magnification 20×, insert 30×). TMAs were immunohistochemically stained for CDK7 and pMED1. The cancer specimen showed a variation in protein expression. The expression of the proteins was homogenous within the patients’ samples, meaning there was little disparity within the staining of cells in a single core. In some HNSCCs the cancer cells showed no staining and accordingly protein expression was considered negative. Throughout the cohort a range of staining intensities was obtained, ( A , B ) illustrate samples of a negative, low, medium, and high protein-expressing tumor specimens.

    Techniques Used: Expressing, Staining

    Scatter plot of CDK7 and pMED1 expression in tissue of ( A ) PTs, ( B ) LNs, ( C ) DMs, and ( D ) RDs. A trendline is shown. Irrespective of the tissue type CDK7 and pMED1 levels showed a significant correlation (DMs p = 0.0019, the rest p < 0.001), while the PCC ranged from 0.39 for LNs to 0.71 for DMs.
    Figure Legend Snippet: Scatter plot of CDK7 and pMED1 expression in tissue of ( A ) PTs, ( B ) LNs, ( C ) DMs, and ( D ) RDs. A trendline is shown. Irrespective of the tissue type CDK7 and pMED1 levels showed a significant correlation (DMs p = 0.0019, the rest p < 0.001), while the PCC ranged from 0.39 for LNs to 0.71 for DMs.

    Techniques Used: Expressing

    Kaplan–Meier graphs with p -values acquired from log-rank tests of ( A ) 5-year OS and ( B ) 5-year DFS. The cohort was stratified into four groups based on CDK7 and pMED1 expression. The expression above the median for the respective protein was considered as a high expression, the expression below the median as low expression. Based on this classification, four groups were formed to display all possible combinations of expression patterns. The log-rank tests revealed no significant difference in 5-year OS or 5-year DFS for the four groups. Nonetheless, we observed that curves grouped by CDK7 expression. There was a trend of shorter 5-year OS and 5-year DFS for both groups with high CDK7 expression compared to the two groups with low CDK7 expression. This effect seemed to be predominant and independent of the pMED1 expression level.
    Figure Legend Snippet: Kaplan–Meier graphs with p -values acquired from log-rank tests of ( A ) 5-year OS and ( B ) 5-year DFS. The cohort was stratified into four groups based on CDK7 and pMED1 expression. The expression above the median for the respective protein was considered as a high expression, the expression below the median as low expression. Based on this classification, four groups were formed to display all possible combinations of expression patterns. The log-rank tests revealed no significant difference in 5-year OS or 5-year DFS for the four groups. Nonetheless, we observed that curves grouped by CDK7 expression. There was a trend of shorter 5-year OS and 5-year DFS for both groups with high CDK7 expression compared to the two groups with low CDK7 expression. This effect seemed to be predominant and independent of the pMED1 expression level.

    Techniques Used: Expressing



    Similar Products

    cdk7 (mo1) mouse mab antibody  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc cdk7 (mo1) mouse mab antibody
    Expression patterns for ( A ) CDK7 and ( B ) <t>pMED1</t> in our HNSCC cohort (magnification 20×, insert 30×). TMAs were immunohistochemically stained for CDK7 and pMED1. The cancer specimen showed a variation in protein expression. The expression of the proteins was homogenous within the patients’ samples, meaning there was little disparity within the staining of cells in a single core. In some HNSCCs the cancer cells showed no staining and accordingly protein expression was considered negative. Throughout the cohort a range of staining intensities was obtained, ( A , B ) illustrate samples of a negative, low, medium, and high protein-expressing tumor specimens.
    Cdk7 (Mo1) Mouse Mab Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk7+(mo1)+mouse+mab+antibody/anti+cdk7/pmc08833595-164-6-33
    Average 90 stars, based on 1 article reviews
    cdk7 (mo1) mouse mab antibody - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Expression patterns for ( A ) CDK7 and ( B ) pMED1 in our HNSCC cohort (magnification 20×, insert 30×). TMAs were immunohistochemically stained for CDK7 and pMED1. The cancer specimen showed a variation in protein expression. The expression of the proteins was homogenous within the patients’ samples, meaning there was little disparity within the staining of cells in a single core. In some HNSCCs the cancer cells showed no staining and accordingly protein expression was considered negative. Throughout the cohort a range of staining intensities was obtained, ( A , B ) illustrate samples of a negative, low, medium, and high protein-expressing tumor specimens.

    Journal: Cancers

    Article Title: CDK7 Predicts Worse Outcome in Head and Neck Squamous-Cell Cancer

    doi: 10.3390/cancers14030492

    Figure Lengend Snippet: Expression patterns for ( A ) CDK7 and ( B ) pMED1 in our HNSCC cohort (magnification 20×, insert 30×). TMAs were immunohistochemically stained for CDK7 and pMED1. The cancer specimen showed a variation in protein expression. The expression of the proteins was homogenous within the patients’ samples, meaning there was little disparity within the staining of cells in a single core. In some HNSCCs the cancer cells showed no staining and accordingly protein expression was considered negative. Throughout the cohort a range of staining intensities was obtained, ( A , B ) illustrate samples of a negative, low, medium, and high protein-expressing tumor specimens.

    Article Snippet: For the staining of CDK7 and pMED1, the following antibodies were used at the indicated dilution after successful control tissue staining according to data sheets: CDK7 (mouse monoclonal, CDK7 (MO1) Mouse mAb, 1:500, Cell Signaling, Danvers, MA, USA) and pMED1 (rabbit polyclonal, Anti-TRAP220/MED1 (phospho T1457) antibody, 1:100, Abcam, Cambridge, UK).

    Techniques: Expressing, Staining

    Scatter plot of CDK7 and pMED1 expression in tissue of ( A ) PTs, ( B ) LNs, ( C ) DMs, and ( D ) RDs. A trendline is shown. Irrespective of the tissue type CDK7 and pMED1 levels showed a significant correlation (DMs p = 0.0019, the rest p < 0.001), while the PCC ranged from 0.39 for LNs to 0.71 for DMs.

    Journal: Cancers

    Article Title: CDK7 Predicts Worse Outcome in Head and Neck Squamous-Cell Cancer

    doi: 10.3390/cancers14030492

    Figure Lengend Snippet: Scatter plot of CDK7 and pMED1 expression in tissue of ( A ) PTs, ( B ) LNs, ( C ) DMs, and ( D ) RDs. A trendline is shown. Irrespective of the tissue type CDK7 and pMED1 levels showed a significant correlation (DMs p = 0.0019, the rest p < 0.001), while the PCC ranged from 0.39 for LNs to 0.71 for DMs.

    Article Snippet: For the staining of CDK7 and pMED1, the following antibodies were used at the indicated dilution after successful control tissue staining according to data sheets: CDK7 (mouse monoclonal, CDK7 (MO1) Mouse mAb, 1:500, Cell Signaling, Danvers, MA, USA) and pMED1 (rabbit polyclonal, Anti-TRAP220/MED1 (phospho T1457) antibody, 1:100, Abcam, Cambridge, UK).

    Techniques: Expressing

    Kaplan–Meier graphs with p -values acquired from log-rank tests of ( A ) 5-year OS and ( B ) 5-year DFS. The cohort was stratified into four groups based on CDK7 and pMED1 expression. The expression above the median for the respective protein was considered as a high expression, the expression below the median as low expression. Based on this classification, four groups were formed to display all possible combinations of expression patterns. The log-rank tests revealed no significant difference in 5-year OS or 5-year DFS for the four groups. Nonetheless, we observed that curves grouped by CDK7 expression. There was a trend of shorter 5-year OS and 5-year DFS for both groups with high CDK7 expression compared to the two groups with low CDK7 expression. This effect seemed to be predominant and independent of the pMED1 expression level.

    Journal: Cancers

    Article Title: CDK7 Predicts Worse Outcome in Head and Neck Squamous-Cell Cancer

    doi: 10.3390/cancers14030492

    Figure Lengend Snippet: Kaplan–Meier graphs with p -values acquired from log-rank tests of ( A ) 5-year OS and ( B ) 5-year DFS. The cohort was stratified into four groups based on CDK7 and pMED1 expression. The expression above the median for the respective protein was considered as a high expression, the expression below the median as low expression. Based on this classification, four groups were formed to display all possible combinations of expression patterns. The log-rank tests revealed no significant difference in 5-year OS or 5-year DFS for the four groups. Nonetheless, we observed that curves grouped by CDK7 expression. There was a trend of shorter 5-year OS and 5-year DFS for both groups with high CDK7 expression compared to the two groups with low CDK7 expression. This effect seemed to be predominant and independent of the pMED1 expression level.

    Article Snippet: For the staining of CDK7 and pMED1, the following antibodies were used at the indicated dilution after successful control tissue staining according to data sheets: CDK7 (mouse monoclonal, CDK7 (MO1) Mouse mAb, 1:500, Cell Signaling, Danvers, MA, USA) and pMED1 (rabbit polyclonal, Anti-TRAP220/MED1 (phospho T1457) antibody, 1:100, Abcam, Cambridge, UK).

    Techniques: Expressing